Persistence and Adherence to ICS/LABA Drugs in UK Patients with Asthma: A Retrospective New-User Cohort Study.
Administration, Inhalation
Adolescent
Adult
Aged
Aged, 80 and over
Androstadienes
/ therapeutic use
Anti-Asthmatic Agents
/ therapeutic use
Asthma
/ drug therapy
Beclomethasone
/ therapeutic use
Benzyl Alcohols
/ therapeutic use
Budesonide, Formoterol Fumarate Drug Combination
/ therapeutic use
Child
Chlorobenzenes
/ therapeutic use
Cohort Studies
Female
Humans
Male
Medication Adherence
/ statistics & numerical data
Middle Aged
Retrospective Studies
United Kingdom
/ epidemiology
Young Adult
Adherence
Asthma
Discontinuation
ICS/LABA
New user
Persistence
Journal
Advances in therapy
ISSN: 1865-8652
Titre abrégé: Adv Ther
Pays: United States
ID NLM: 8611864
Informations de publication
Date de publication:
06 2020
06 2020
Historique:
received:
11
03
2020
pubmed:
4
5
2020
medline:
23
2
2021
entrez:
4
5
2020
Statut:
ppublish
Résumé
Asthma is associated with significant economic burden. Inhaled corticosteroid and long-acting beta A retrospective new-user active comparator database study was conducted in the IQVIA Medical Research Database. Propensity score (PS) matching was performed for FF/VI versus BUD/FM, and FF/VI versus BDP/FM. The primary objective was to compare patient treatment persistence (time to discontinuation), while secondary objectives included assessing adherence (mean proportion of days covered [PDC] with medication in the study period) and the proportions of patients achieving ≥ 50% and ≥ 80% PDC. New users of FF/VI (N = 966), BUD/FM (N = 5931) and BDP/FM (N = 9607) were identified and PS-matched: FF/VI (n = 945) versus BUD/FM (n = 3272), and FF/VI (n = 902) versus BDP/FM (n = 3465). At 12 months, treatment persistence was 69% (FF/VI), 53% (BUD/FM) and 57% (BDP/FM). The likelihood of treatment discontinuation within 12 months after initiation with FF/VI was 35% lower than with BUD/FM and 31% lower than for BDP/FM (both p < 0.001). Mean PDC was higher for FF/VI compared with BUD/FM (77.7 vs 72.4; p < 0.0001) and BDP/FM (78.2 vs 71.0; p < 0.0001). The odds of achieving ≥ 50% and ≥ 80% PDC were greater for FF/VI than for BUD/FM and BDP/FM. In this study, patients who initiated FF/VI were less likely to discontinue treatment and showed greater treatment adherence versus patients who initiated BUD/FM or BDP/FM.
Identifiants
pubmed: 32361850
doi: 10.1007/s12325-020-01344-8
pii: 10.1007/s12325-020-01344-8
pmc: PMC7467428
doi:
Substances chimiques
Androstadienes
0
Anti-Asthmatic Agents
0
Benzyl Alcohols
0
Budesonide, Formoterol Fumarate Drug Combination
0
Chlorobenzenes
0
Beclomethasone
KGZ1SLC28Z
Types de publication
Comparative Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Pagination
2916-2931Références
British Lung Foundation. Asthma statistics, 2018. https://statistics.blf.org.uk/asthma . Accessed 11 Mar 2020.
2019 Pocket Guide for Asthma Management and Prevention. https://ginasthma.org/pocket-guide-for-asthma-management-and-prevention/ . Accessed 11 Mar 2020.
Miller-Larsson A, Selroos O. Advances in asthma and COPD treatment: combination therapy with inhaled corticosteroids and long-acting beta 2-agonists. Curr Pharm Des. 2006;12:3261–79.
doi: 10.2174/138161206778194187
Electronic Medicines Compendium. Fostair 100/6 inhalation solution. August 2018. https://www.medicines.org.uk/emc/product/6318/smpc . Accessed 11 Mar 2020.
AstraZeneca Canada SYMBICORT
European Medicines Agency. Relvar Ellipta product monograph. August 2018. https://www.ema.europa.eu/en/documents/product-information/relvar-ellipta-epar-product-information_en.pdf . Accessed 11 Mar 2020.
Woodcock A, Vestbo J, Bakerly ND, et al. Effectiveness of fluticasone furoate plus vilanterol on asthma control in clinical practice: an open-label, parallel group, randomised controlled trial. Lancet. 2017;390:2247–55.
doi: 10.1016/S0140-6736(17)32397-8
Jacques L, Bakerly ND, New JP, Svedsater H, Lay-Flurrie J, Leather DA. Effectiveness of fluticasone furoate/vilanterol versus fluticasone propionate/salmeterol on asthma control in the Salford Lung Study. J Asthma. 2019;56:748–57.
doi: 10.1080/02770903.2018.1490751
Averell CS, Stanford R, Laliberte F, Wu J, Germain G, Duh M. Adherence with once-daily fluticasone furoate/vilanterol compared to twice-daily budesonide/formoterol or fluticasone propionate/salmeterol in asthma. Ann Allergy Asthma Immunol. 2018;121:S39.
doi: 10.1016/j.anai.2018.09.124
Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health. 2008;11:44–7.
doi: 10.1111/j.1524-4733.2007.00213.x
Brown MT, Bussell JK. Medication adherence: WHO cares? Mayo Clin Proc. 2011;86:304–14.
doi: 10.4065/mcp.2010.0575
Price D, Brusselle G, Roche N, Freeman D, Chisholm A. Real-world research and its importance in respiratory medicine. Breathe. 2015;11:26–38.
doi: 10.1183/20734735.015414
Engelkes M, Janssens HM, de Jongste JC, Sturkenboom MC, Verhamme KM. Medication adherence and the risk of severe asthma exacerbations: a systematic review. Eur Respir J. 2015;45:396–407.
doi: 10.1183/09031936.00075614
van der Palen J, Thomas M, Chrystyn H, et al. A randomised open-label cross-over study of inhaler errors, preference and time to achieve correct inhaler use in patients with COPD or asthma: comparison of ELLIPTA with other inhaler devices. NPJ Prim Care Respir Med. 2016;26:16079.
doi: 10.1038/npjpcrm.2016.79
Svedsater H, Jacques L, Goldfrad C, Bleecker ER. Ease of use of the ELLIPTA dry powder inhaler: data from three randomised controlled trials in patients with asthma. NPJ Prim Care Respir Med. 2014;24:14019.
doi: 10.1038/npjpcrm.2014.19
Murphy KR, Bender BG. Treatment of moderate to severe asthma: patient perspectives on combination inhaler therapy and implications for adherence. J Asthma Allergy. 2009;2(63–72):17.
The Health Improvement Network (THIN). https://www.visionhealth.co.uk/portfolio-items/the-health-improvement-network-thin/ . Accessed 11 Mar 2020
Suissa S. Immortal time bias in pharmacoepidemiology. Am J Epidemiol. 2007;167:492–9.
doi: 10.1093/aje/kwm324
Haynes RB, Taylor DW, Sackett DL, Gibson ES, Bernholz CD, Mukherjee J. Can simple clinical measurements detect patient noncompliance? Hypertension. 1980;2(6):757–64.
doi: 10.1161/01.HYP.2.6.757
Baumgartner PC, Haynes RB, Arnet I, et al. A systematic review of medication adherence thresholds dependent of clinical outcomes. Front Pharmacol. 2018;9:1290.
doi: 10.3389/fphar.2018.01290
Averell CM, Stanford RH, Laliberte F, Wu JW, Germain G, Duh MS. Medication adherence in patients with asthma using once-daily versus twice-daily ICS/LABAs. J Asthma. 2019;1:1–10. https://doi.org/10.1080/02770903.2019.1663429 .
doi: 10.1080/02770903.2019.1663429
Wu AC, Butler MG, Li L, et al. Primary adherence to controller medications for asthma is poor. Ann Am Thorac Soc. 2015;12:161–6. https://doi.org/10.1513/AnnalsATS.201410-459OC .
doi: 10.1513/AnnalsATS.201410-459OC
pubmed: 25569765
pmcid: 4342835
Makhinova T, Barner JC, Richards KM, Rascati KL. Asthma controller medication adherence, risk of exacerbation, and use of rescue agents among texas medicaid patients with persistent asthma. J Manag Care Spec Pharm. 2015;21:1124–32. https://doi.org/10.18553/jmcp.2015.21.12.1124 .
doi: 10.18553/jmcp.2015.21.12.1124
pubmed: 26679962
Boutopoulou B, Koumpagioti D, Matziou V, Priftis KN, Douros K. Interventions on adherence to treatment in children with severe asthma: a systematic review. Front Pediatr. 2018;6:232.
doi: 10.3389/fped.2018.00232
Stanford RH, Averell C, Parker ED, Blauer-Peterson C, Reinsch TK, Buikema AR. Assessment of adherence and asthma medication ratio (AMR) for a once-daily and twice-daily inhaled corticosteroid/long acting beta agonist (ICS/LABA) for asthma. J Allergy Clin Immunol Pract. 2019;7(14–1496):e7. https://doi.org/10.1016/j.jaip.2018.12.021 .
doi: 10.1016/j.jaip.2018.12.021
Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med. 2009;28:3083–107.
doi: 10.1002/sim.3697
Sovani MP, Whale CI, Oborne J, et al. Poor adherence with inhaled corticosteroids for asthma: can using a single inhaler containing budesonide and formoterol help? Br J Gen Pract. 2008;58:37–433.
doi: 10.3399/bjgp08X263802
Berger WE. The use of inhaled formoterol in the treatment of asthma. Ann Allergy Asthma Immunol. 2006;97(1):24–33.
doi: 10.1016/S1081-1206(10)61365-8
THIN-HES Privacy Notice. https://www.iqvia.com/locations/united-kingdom/information-for-members-of-the-public/thin-hes-data . Accessed 01 Apr 2020.
Lund JL, Richardson DB, Sturmer T. The active comparator, new user study design in pharmacoepidemiology: historical foundations and contemporary application. Curr Epidemiol Rep. 2015;2:221–8.
doi: 10.1007/s40471-015-0053-5
AstraZeneca launches Symbicort SMART in UK. https://www.thepharmaletter.com/article/astrazeneca-launches-symbicort-smart-in-uk . Accessed 02 April 2020.
Fostair launched in UK as cheaper than GSK/AZ asthma MDIs. https://www.thepharmaletter.com/article/fostair-launched-in-uk-as-cheaper-than-gsk-az-asthma-mdis . Accessed 02 April 2020.
Asthma: fluticasone furoate/vilanterol (Relvar Ellipta) combination inhaler. https://www.nice.org.uk/advice/esnm34/chapter/product-overview . Accessed 02 Apr 2020.
Pharmacy Quality Alliance. Adherence: PQA adherence measures. https://www.pqaalliance.org/adherence-measures . Accessed 11 Mar 2020.
Stanford RH, Averell C, Parker ED, Blauer-Peterson C, Reinsch TK, Buikema AR. Assessment of adherence and asthma medication ratio for a once-daily and twice-daily inhaled corticosteroid/long-acting beta-agonist for asthma. J Allergy Clin Immunol Pract. 2019;7(1488–96):e7.
Atsuta R, TakaiIsao J, Mukai I, Kobayashi A, Ishii T, Svedsater H. Patients with asthma prescribed once-daily fluticasone furoate/vilanterol or twice-daily fluticasone propionate/salmeterol as maintenance treatment: analysis from a claims database. Pulm Ther. 2018;4:135–47.
doi: 10.1007/s41030-018-0084-4